Everything tagged "drug manufacturers general" across research, earnings, and macro.
7 articles
Novo Nordisk remains a premier cardiometabolic franchise, but near-term pricing pressure and a weak 2026 outlook are tempering the story. The stock looks attractive for patient investors who can look through the reset and wait for obesity and pipeline reacceleration.
Merck combines elite cash generation with a growing pipeline, but KEYTRUDA still drives nearly half of sales. The stock looks like a quality compounder as new launches help reduce concentration risk.
Biogen is no longer just a declining MS story. Q1 2026 showed rising EPS, stronger free cash flow, and growing newer products, but full-year revenue still faces pressure.
Sanofi is becoming a more focused biopharma compounder, led by Dupixent growth, vaccine strength, and expanding launch sales. The stock looks inexpensive versus its cash generation and earnings power.
Amgen is growing through patent expirations with broad-based momentum across Repatha, rare disease, oncology, and biosimilars. The stock looks like a Buy, though valuation already reflects much of the resilience.
Eli Lilly is delivering exceptional revenue and EPS growth, led by Mounjaro and Zepbound, while raising 2026 guidance again. The stock is expensive, but the franchise momentum and pipeline breadth keep the long-term case intact.
GSK is evolving from a mature pharma cash generator into a more balanced growth story, with Specialty Medicines driving faster growth and margins improving. The stock still looks reasonably valued versus its earnings power and pipeline.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator